Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017394 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00017394: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00017394 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017394, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of bevacizumab combined with vinorelbine in treating patients who have stage IV breast cancer. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody with chemotherapy may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL bevacizumab
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2001-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017394
The ClinicalTrials.gov registry entry for NCT00017394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00017394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017394 about?
NCT00017394 is a clinical study titled "Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer". Phase II trial to study the effectiveness of bevacizumab combined with vinorelbine in treating patients who have stage IV breast cancer. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Dru...
What is the current status of trial NCT00017394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2001-03.
What interventions are being tested in trial NCT00017394?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bevacizumab (BIOLOGICAL), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00017394?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.